ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Top Cited Papers
- 14 March 2012
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (6), 1494-1503
- https://doi.org/10.1158/0008-5472.CAN-11-3948
Abstract
Continued reliance on the androgen receptor (AR) is now understood as a core mechanism in castration-resistant prostate cancer (CRPC), the most advanced form of this disease. While established and novel AR pathway-targeting agents display clinical efficacy in metastatic CRPC, dose-limiting side effects remain problematic for all current agents. In this study, we report the discovery and development of ARN-509, a competitive AR inhibitor that is fully antagonistic to AR overexpression, a common and important feature of CRPC. ARN-509 was optimized for inhibition of AR transcriptional activity and prostate cancer cell proliferation, pharmacokinetics, and in vivo efficacy. In contrast to bicalutamide, ARN-509 lacked significant agonist activity in preclinical models of CRPC. Moreover, ARN-509 lacked inducing activity for AR nuclear localization or DNA binding. In a clinically valid murine xenograft model of human CRPC, ARN-509 showed greater efficacy than MDV3100. Maximal therapeutic response in this model was achieved at 30 mg/kg/d of ARN-509, whereas the same response required 100 mg/kg/d of MDV3100 and higher steady-state plasma concentrations, Thus, ARN-509 exhibits characteristics predicting a higher therapeutic index with a greater potential to reach maximally efficacious doses in man than current AR antagonists. Our findings offer preclinical proof of principle for ARN-509 as a promising therapeutic in both castration-sensitive and castration-resistant forms of prostate cancer. Cancer Res; 72(6); 1494-503. (C) 2012 AACRKeywords
Other Versions
This publication has 17 references indexed in Scilit:
- Abiraterone and Increased Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2011
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate CancerCancer Cell, 2011
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2010
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone AcetateJournal of Clinical Oncology, 2010
- Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established targetThe Lancet Oncology, 2009
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- Androgen receptor: A key molecule in the progression of prostate cancer to hormone independenceJournal of Cellular Biochemistry, 2003